

ZOGENIX, INC.
Form 8-K
November 03, 2016

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 31, 2016

ZOGENIX, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware
(State or Other Jurisdiction

of Incorporation)

001-34962
(Commission

File Number)

20-5300780
(IRS Employer

Identification No.)

5858 Horton Street, #455, Emeryville, CA
(Address of Principal Executive Offices)

94608
(Zip Code)

Registrant's telephone number, including area code: (510) 550-8300

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01 Entry into a Material Definitive Agreement.

On October 31, 2016, Zogenix, Inc. (the Company) and Patheon UK Limited (Patheon) entered into an amendment (the Amendment) to the Manufacturing Services Agreement, dated February 28, 2013, as amended to date, by and between the Company and Patheon (the Services Agreement). Under the terms of the Services Agreement, Patheon serves as the Company's exclusive manufacturer for the aseptic capsule assembly, filling and inspection, final system assembly and packaging of Sumavel® DosePro®, and also supplies other manufacturing and support services. Pursuant to the Amendment, the expiration of the term of the Services Agreement has been extended to April 30, 2017. The parties may mutually agree in writing to renew the term for additional terms prior to the expiration of the then-current term.

* * *

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by the Amendment, a copy of which the Company intends to file with its Annual Report on Form 10-K for the year ending December 31, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ZOGENIX, INC.

Date: November 3, 2016

By: /s/ Ann D. Rhoads
Name: Ann D. Rhoads
Title: Executive Vice President,

Chief Financial Officer,

Treasurer and Secretary